UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 67

Sortiert nach

Transplant-Associated Thrombotic Microangiopathy Is a Multifactorial Disease Unresponsive to Immunosuppressant Withdrawal

Biology of blood and marrow transplantation, 2019-03, Vol.25 (3), p.570-576

2019

Volltextzugriff (PDF)

Reimagining Cancer Staging in the Era of Evolutionary Oncology

Journal of the National Comprehensive Cancer Network, 2022-12, Vol.20 (12), p.1370

2022

Volltextzugriff (PDF)

Safety outcomes of pembrolizumab with platinum agent chemotherapy combined with 5-fluorouracil or taxane derivative in head and neck cancer

Journal of oncology pharmacy practice, 2023-12, p.10781552231217686-10781552231217686

2023

Volltextzugriff (PDF)

Promise of Patient-Reported Outcomes, Biometric Data, and Remote Monitoring for Adoptive Cellular Therapy

JCO clinical cancer informatics, 2022-05, Vol.6, p.e2200013

2022

Volltextzugriff (PDF)

Change in Patients’ Perceived Cognition Following Chimeric Antigen Receptor T-Cell Therapy for Lymphoma

Transplantation and cellular therapy, 2022-07, Vol.28 (7), p.401.e1-401.e7

2022

Volltextzugriff (PDF)

Oncology Providers' and Professionals' Experiences With Suicide Risk Screening Among Patients With Head and Neck Cancer: A Qualitative Study

JCO oncology practice, 2023-06, Vol.19 (6), p.e892-e903

2023

Volltextzugriff (PDF)

Abstract 5538: Prevalence of factors serving as common cancer clinical trial eligibility criteria by race and ethnicity

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.5538-5538

2023

Volltextzugriff (PDF)

The History and Future of Multidisciplinary Cancer Care

Seminars in radiation oncology

Volltextzugriff (PDF)

Racial and ethnic disparities in hematologic malignancies

Blood, 2017-10, Vol.130 (15), p.1699-1705

2017

Volltextzugriff (PDF)

Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead

Journal for immunotherapy of cancer, 2021-07, Vol.9 (7), p.e002723

2021

Volltextzugriff (PDF)

Recent Advances and Future Directions in Clinical Management of Head and Neck Squamous Cell Carcinoma

Cancers, 2021-01, Vol.13 (2), p.338

2021

Volltextzugriff (PDF)

Emerging Therapies for Radioactive Iodine Refractory Thyroid Cancer

Current treatment options in oncology, 2020-02, Vol.21 (3), p.18-18, Article 18

2020

Volltextzugriff (PDF)

TCR gene-engineered cell therapy for solid tumors

Best practice & research. Clinical haematology, 2021-09, Vol.34 (3), p.101285-101285, Article 101285

2021

Volltextzugriff (PDF)

“I have cancer during COVID; that’s a special category”: a qualitative study of head and neck cancer patient and provider experiences during the COVID-19 pandemic

Supportive care in cancer, 2022-05, Vol.30 (5), p.4337-4344

2022

Volltextzugriff (PDF)

Molecular characterization of the salivary adenoid cystic carcinoma immune landscape by anatomic subsites

Scientific reports, 2024-07, Vol.14 (1), p.15821-13, Article 15821

2024

Volltextzugriff (PDF)

169 Outcomes of Stereotactic Body Radiation Therapy for Re-Irradiation of Squamous Carcinomas of the Head and Neck

Radiotherapy and oncology, 2024-03, Vol.192, p.S45-S46

2024

Volltextzugriff (PDF)

Association between human papillomavirus (HPV) status and duration of response of anti-programmed cell death protein-1 (PD-1) inhibitors in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.6044-6044

2019

Volltextzugriff (PDF)

Postoperative Combined Modality Treatment in High Risk Resected Locally Advanced Squamous Cell Carcinomas of the Head and Neck (HNSCC)

Frontiers in oncology, 2018-12, Vol.8, p.588-588

2018

Volltextzugriff (PDF)

Gut microbiome/metabolome predicts response to immune checkpoint blockers (ICB) in patients with recurrent metastatic head and neck squamous cell cancer (RM HNSCC)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.6055-6055

2022

Volltextzugriff (PDF)

Phase I dose escalation of stereotactic body radiation therapy and concurrent cisplatin for re-irradiation of unresectable, recurrent head and neck squamous cell carcinoma

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.6543-6543

2020

Volltextzugriff (PDF)

Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline

Journal of clinical oncology, 2023-02, Vol.41 (5), p.1132-1146

2023

Volltextzugriff (PDF)

Survival results of phase I dose escalation of stereotactic body radiation therapy and concurrent cisplatin for re-irradiation of unresectable, recurrent head and neck squamous cell carcinoma

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e18020-e18020

2021

Volltextzugriff (PDF)

Phase II Multi-institutional Clinical Trial Result of Concurrent Cetuximab and Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

Clinical cancer research, 2022-06, Vol.28 (11), p.2329-2338

2022

Volltextzugriff (PDF)

Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial

Nature medicine, 2023-04, Vol.29 (4), p.880-887

2023

Volltextzugriff (PDF)

1 – 25 von 67

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(66)
Mit Volltextzugriff
(60)

Publikationsform

Artikel
(67)

Sprache

Englisch
(67)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Transplant-Associated Thrombotic Microangiopathy Is a Multifactorial Disease Unresponsive to Immunosuppressant Withdrawal

Reimagining Cancer Staging in the Era of Evolutionary Oncology

Safety outcomes of pembrolizumab with platinum agent chemotherapy combined with 5-fluorouracil or taxane derivative in head and neck cancer

Promise of Patient-Reported Outcomes, Biometric Data, and Remote Monitoring for Adoptive Cellular Therapy

Change in Patients’ Perceived Cognition Following Chimeric Antigen Receptor T-Cell Therapy for Lymphoma

Oncology Providers' and Professionals' Experiences With Suicide Risk Screening Among Patients With Head and Neck Cancer: A Qualitative Study

Abstract 5538: Prevalence of factors serving as common cancer clinical trial eligibility criteria by race and ethnicity

The History and Future of Multidisciplinary Cancer Care

Racial and ethnic disparities in hematologic malignancies

Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead

Recent Advances and Future Directions in Clinical Management of Head and Neck Squamous Cell Carcinoma

Emerging Therapies for Radioactive Iodine Refractory Thyroid Cancer

TCR gene-engineered cell therapy for solid tumors

“I have cancer during COVID; that’s a special category”: a qualitative study of head and neck cancer patient and provider experiences during the COVID-19 pandemic

Molecular characterization of the salivary adenoid cystic carcinoma immune landscape by anatomic subsites

169 Outcomes of Stereotactic Body Radiation Therapy for Re-Irradiation of Squamous Carcinomas of the Head and Neck

Association between human papillomavirus (HPV) status and duration of response of anti-programmed cell death protein-1 (PD-1) inhibitors in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)

Postoperative Combined Modality Treatment in High Risk Resected Locally Advanced Squamous Cell Carcinomas of the Head and Neck (HNSCC)

Gut microbiome/metabolome predicts response to immune checkpoint blockers (ICB) in patients with recurrent metastatic head and neck squamous cell cancer (RM HNSCC)

Phase I dose escalation of stereotactic body radiation therapy and concurrent cisplatin for re-irradiation of unresectable, recurrent head and neck squamous cell carcinoma

Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline

Survival results of phase I dose escalation of stereotactic body radiation therapy and concurrent cisplatin for re-irradiation of unresectable, recurrent head and neck squamous cell carcinoma

Concurrent Cetuximab and Nivolumab as a Second-Line or beyond Treatment of Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results of Phase I/II Study

Phase II Multi-institutional Clinical Trial Result of Concurrent Cetuximab and Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial

Suchergebnisse filtern